摘要
表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors, EGFRTKIs)和作用于程序性死亡受体-1(programmed death receptor, PD-1)/程序性死亡配体-1(programmed death ligand 1,PD-L1)的免疫检查点抑制剂是非小细胞肺癌(non-small cell lung cancer, NSCLC)治疗中具有里程碑意义的药物。然而,EGFR突变的NSCLC患者中PD-L1表达调控机制尚不完全清楚,可能涉及多条信号通路。本文就此进行综述,为探索EGFR突变和PD-L1表达之间的关系,以及指导创新性的NSCLC免疫化学治疗的策略提供科学依据。
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)and programmed death receptor i (PD-1)/programmed death ligand 1(PD-L1)immune checkpoint inhibitors were landmarks in the treatment of non-small cell lung cancer (NSCLC).However,the regulation mechanisms of PD-L1expression were not fully clear in NSCLC patients with EGFR mutations.Multiple signaling pathways may be involved in the tumorigenesis regulation.This paper sum- marized and reviewed the potential EGFR mutations impacting on PD-L1expression with aims to the development of strate- gies on immunochemical therapy for NSCLC.
作者
冷雪峰
梅建东
刘伦旭
Xuefeng LENG;Jiandong MEI;Lunxu LIU(Department of Thoracic Surgery,West China Hospitalj Sichuan University,Chengdu 610041,China;Division of Thoracic Surgery,Sichuan Cancer Hospital and Institute,Cancer Hospital Affiliated to School of Medicine,University of Electronic Science and Technology of China (UESTC),Chengdu610041,China)
出处
《中国肺癌杂志》
CAS
CSCD
北大核心
2018年第11期875-879,共5页
Chinese Journal of Lung Cancer
基金
国家自然科学基金项目(No.81602025)资助~~
关键词
表皮生长因子受体
程序性死亡配体-1
信号通路
肺肿瘤
Epidermal growth factor receptor
Programmed death ligand 1
Signaling pathways
Lung neoplasms
